BioCellgraft has signed an exclusive deal to distribute placental-derived biomaterials for use in dental procedures manufactured by Celularity in the U.S.
BioCellgraft will market the products under private label brands that are expected to be announced in early 2024. Some products are used to augment or correct soft tissue, while others are used as a barrier membrane in periodontology, implant dentistry, and oral surgery procedures. Terms of the agreement were not disclosed.
